Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Predictors of the primary response to biologic treatment [anti-TNF, Vedolizumab and Ustekinumab] in patients with inflammation of the gut : from basic science to clinical practice.